Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

A new study found that aged neurons have defects in key proteins that make them vulnerable to molecular stress and neurodegenerative damage.

Bora Pharmaceuticals also offers lyophilization, terminal sterilization, analytical, stability, and packaging and serialization services.